Optogenetic and chemogenetic manipulations of striatal output pathways for seizure control

Information

  • Research Project
  • 10238003
  • ApplicationId
    10238003
  • Core Project Number
    F30NS110318
  • Full Project Number
    5F30NS110318-03
  • Serial Number
    110318
  • FOA Number
    PA-18-673
  • Sub Project Id
  • Project Start Date
    9/1/2019 - 4 years ago
  • Project End Date
    9/30/2023 - 8 months ago
  • Program Officer Name
    CHURN, SEVERN BORDEN
  • Budget Start Date
    9/1/2021 - 2 years ago
  • Budget End Date
    8/31/2022 - a year ago
  • Fiscal Year
    2021
  • Support Year
    03
  • Suffix
  • Award Notice Date
    8/6/2021 - 2 years ago
Organizations

Optogenetic and chemogenetic manipulations of striatal output pathways for seizure control

Project Abstract Deep brain stimulation for epilepsy is growing in use, and offers promise to patients for whom other treatments fail. Thus, identifying new targets for stimulation is of considerable clinical and translational interest. The basal ganglia (BG), which have been explored extensively for stimulation in movement disorders, also may be attractive targets for epilepsy. Preclincial studies show that modulating activity in BG nuclei such as the striatum and substantia nigra pars reticulata (SNpr) can potently suppress experimental seizures in acute models of epilepsy. However, the network mechanisms underlying this effect, and the degree to which this translates into models of chronic epilepsy remain unknown. This NRSA F30 proposal requests four years of support. During years 1 and 2, I plan to complete my doctoral thesis. The thesis will encompass the two aims presented in the following research plan that have been heavily updated to reflect my research progress since the submission of the original proposal. In aim 1, I will test the hypothesis that on-demand optogenetic silencing of the SNpr will suppress spontaneous seizures in chronically epileptic rats. In parallel, I will test the hypothesis that on-demand activation of the striatum will produce an equivalent suppression of spontaneous seizures. While these manipulations are well-studied in acute seizure models, these studies would be the first to evaluate the anticonvulsant potential of these regions in chronic epilepsy. During the course of this aim, I will learn the status epilepticus model of chronic epilepsy in rats and the set up of self-contained, automated systems to monitor their seizure activity. In aim 2, I will use fiber photometry to test the hypothesis that seizure activity progressively and differentially engages basal ganglia output pathways. I will also test the hypothesis that optogenetic manipulations that counteract pathological recruitment of striatal pathways will suppress seizures. The training in this aim includes learning the technical aspects of fiber photometry as well as coding and data analysis methods. Throughout the course of my doctoral research, I will continue to be trained in physiological and histological methods as well as general skills and career development. After I complete my thesis defense, I will complete my pre-doctoral medical training during years 3 and 4 of the fellowship period. Clinical training follows a standardized institutional curriculum. After this period of joint-degree training, I plan to apply to combined residency/fellowship tracks in physician-scientist training programs in neurology/epileptology. In sum, during the proposed fellowship period, I will gain expertise in cutting-edge techniques in neurophysiology concurrent with training in intellectual and practical career development. The work proposed will benefit the field by determining mechanisms of seizure propagation and restraint via basal ganglia nodes while also testing them as candidates for the management of chronic spontaneous epilepsies.

IC Name
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
  • Activity
    F30
  • Administering IC
    NS
  • Application Type
    5
  • Direct Cost Amount
    51036
  • Indirect Cost Amount
  • Total Cost
    51036
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    853
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
    NINDS:51036\
  • Funding Mechanism
    TRAINING, INDIVIDUAL
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    GEORGETOWN UNIVERSITY
  • Organization Department
    PHARMACOLOGY
  • Organization DUNS
    049515844
  • Organization City
    WASHINGTON
  • Organization State
    DC
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    200570001
  • Organization District
    UNITED STATES